Among them, relatlimab was approved by the U.S. Food and Drug Administration (FDA) in 2022 for use in combination with the PD - 1 inhibitor nivolumab at a fixed dose regimen for the treatment of unresectable or metastatic melanoma, marking LAG - 3 as the third immune checkpoint approved for clinical use (17, 18). This evidence concerns the gene RPL17 and metastatic melanoma.